Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 5/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.38 |
| ▸ | ESRRG | P62508 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5536102 | 0.93 | GRM5 (0.40) | PIN1GRM5RCE1MAPTKMT2A | |
| SCHEMBL5522276 | 0.92 | MAPT (0.41) | PIN1GRM5MAPTKMT2AMEN1 | |
| SCHEMBL5524589 | 0.89 | GRM5 (0.40) | PIN1GRM5KMT2A | |
| SCHEMBL5530770 | 0.88 | GRM5 (0.38) | PIN1GRM5MAPTKMT2AMEN1 | |
| SCHEMBL3272609 | 0.87 | GRM5 (0.41) | GRM5 | |
| SCHEMBL5522295 | 0.86 | GRM5 (0.38) | PIN1GRM5MAPTLPAR1LPAR5 | |
| SCHEMBL5527039 | 0.86 | GRM5 (0.38) | GRM5MAPTLPAR1LPAR5 | |
| SCHEMBL5528458 | 0.86 | GRM5 (0.38) | PIN1GRM5MAPTLPAR1LPAR5 | |
| SCHEMBL5531707 | 0.86 | GRM5 (0.36) | PIN1GRM5MAPTNR1H4ESRRG | |
| SCHEMBL5531740 | 0.86 | PIN1 (0.45) | PIN1GRM5RCE1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185154-A1 | 1H-pyrrolo[2,3-c]pyridine-7-carboxylic acid (4-tert-butyl-benzyl)-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-amide; cardiovascular diseases such as atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemi | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | claimed |
| US-20070185154-A1 | 1H-pyrrolo[2,3-c]pyridine-7-carboxylic acid (4-tert-butyl-benzyl)-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-amide; cardiovascular diseases such as atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemi | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185154-A1 | 1H-pyrrolo[2,3-c]pyridine-7-carboxylic acid (4-tert-butyl-benzyl)-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-amide; cardiovascular diseases such as atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemi | APOB, CETP, LIPC | PIN1 2667/4885GRM5 4093/4885RCE1 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.